Holding company Blackhawk Growth Corp.(OTC:BLRZF)'s subsidiary company MindBio Therapeutics Pty Ltd shared the positive data gathered from its Phase 1 clinical trials microdosing LSD formulation in 80 healthy participants.
A practical summary of the outcomes collected at this stage: microdoses of LSD have not shown severe adverse effects -though jitteriness can emerge in some patients- and increases in energy, wellness, happiness, creativity and connectedness suggest anti-anhedonic properties to improve treatment of patients with depression, home-based microdosing studies seem to be feasible and practical, and a subtle dose measuring and adjustment could optimize the treatment regimen.
